Effects of oral supplementation with probiotics or synbiotics in overweight and obese adults: a systematic review and meta-analyses of randomized trials

Suzumura, Érica Aranha; Bersch-Ferreira, Ângela Cristine; Torreglosa, Camila Ragne; Silva, Jacqueline T. da; Coqueiro, Audrey Yule; Kuntz, Marilyn Gonçalves Ferreira; Chrispim, Pedro Paulo Magalhães; Weber, Bernardete; Cavalcanti, Alexandre Biasi

doi:10.1093/nutrit/nuz001

Cited by 62 publications

(58 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…www.nature.com/scientificreports www.nature.com/scientificreports/ meta-analyses [21][22][23][24] . Supplementation with Lab4P had a greater impact on females (SG2b), who lost more weight than males (SG2a).…”

Section: Discussionmentioning

confidence: 99%

“…In the most recent meta-analyses detailing probiotics and weight loss, body weight reductions up to 1.05 kg and BMI reductions up to 0.55 kg/m 2 have been reported for overweight/obese subjects 10,22,27 . Studies focusing on free-living overweight and/or obese participants present variable outcomes [18][19][20][28][29][30][31][32][33][34] with many performed in Asian populations 18,[29][30][31][32][33][34] .…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A randomised controlled study shows supplementation of overweight and obese adults with lactobacilli and bifidobacteria reduces bodyweight and improves well-being

Michael

Jack

Masetti

et al. 2020

Sci Rep

View full text Add to dashboard Cite

in an exploratory, block-randomised, parallel, double-blind, single-centre, placebo-controlled superiority study (ISRCTN12562026, funded by Cultech Ltd), 220 Bulgarian participants (30 to 65 years old) with BMI 25-34.9 kg/m 2 received Lab4P probiotic (50 billion/day) or a matched placebo for 6 months. Participants maintained their normal diet and lifestyle. primary outcomes were changes in body weight, BMi, waist circumference (WC), waist-to-height ratio (WtHR), blood pressure and plasma lipids. Secondary outcomes were changes in plasma C-reactive protein (CRP), the diversity of the faecal microbiota, quality of life (QoL) assessments and the incidence of upper respiratory tract infection (URTI). Significant between group decreases in body weight (1.3 kg, p < 0.0001), BMI (0.045 kg/m 2 , p < 0.0001), WC (0.94 cm, p < 0.0001) and WtHR (0.006, p < 0.0001) were in favour of the probiotic. Stratification identified greater body weight reductions in overweight subjects (1.88%, p < 0.0001) and in females (1.62%, p = 0.0005). Greatest weight losses were among probiotic hypercholesterolaemic participants (−2.5%, p < 0.0001) alongside a significant between group reduction in small dense LDL-cholesterol (0.2 mmol/L, p = 0.0241). Improvements in QoL and the incidence rate ratio of URTI (0.60, p < 0.0001) were recorded for the probiotic group. No adverse events were recorded. Six months supplementation with Lab4P probiotic resulted in significant weight reduction and improved small dense low-density lipoprotein-cholesterol (sdLDL-C) profiles, QoL and URTI incidence outcomes in overweight/obese individuals. World Health Organisation (WHO) global estimates indicate that 39% of adults are overweight and 13% are obese and trends suggest that levels will continue to rise as a result of current dietary habits and sedentary lifestyles 1. The burden of obesity on primary healthcare providers is substantial and it is estimated that, in England alone in 2013, excess body weight in women cost £2.2 billion in consultations and £1.9 billion for prescription medications 2. One of the consequences of obesity is the increased incidence of Metabolic Syndrome (MetS)-an umbrella term used for a cluster of interrelated metabolic conditions linked with obesity including hypercholesterolaemia,

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

A randomised controlled study shows supplementation of overweight and obese adults with lactobacilli and bifidobacteria reduces bodyweight and improves well-being

Michael

Jack

Masetti

et al. 2020

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Dietary intervention with probiotics, prebiotics or synbiotics (which combine probiotic and prebiotic components) aimed at correcting disruption of the gut microbiota observed in obesity or following imbalanced diets may provide health benefits by facilitating weight loss and maintenance [19,20]. Recent human and animal studies have suggested that probiotics can promote weight loss in obesity [21,22], but studies on the role of synbiotics in obesity are very limited [23,24] and further studies are warranted [23].…”

Section: Introductionmentioning

confidence: 99%

Effects of Synbiotic Supplement on Human Gut Microbiota, Body Composition and Weight Loss in Obesity

et al. 2020

View full text Add to dashboard Cite

Targeting gut microbiota with synbiotics (probiotic supplements containing prebiotic components) is emerging as a promising intervention in the comprehensive nutritional approach to reducing obesity. Weight loss resulting from low-carbohydrate high-protein diets can be significant but has also been linked to potentially negative health effects due to increased bacterial fermentation of undigested protein within the colon and subsequent changes in gut microbiota composition. Correcting obesity-induced disruption of gut microbiota with synbiotics can be more effective than supplementation with probiotics alone because prebiotic components of synbiotics support the growth and survival of positive bacteria therein. The purpose of this placebo-controlled intervention clinical trial was to evaluate the effects of a synbiotic supplement on the composition, richness and diversity of gut microbiota and associations of microbial species with body composition parameters and biomarkers of obesity in human subjects participating in a weight loss program. The probiotic component of the synbiotic used in the study contained Lactobacillus acidophilus, Bifidobacterium lactis, Bifidobacterium longum, and Bifidobacterium bifidum and the prebiotic component was a galactooligosaccharide mixture. The results showed no statistically significant differences in body composition (body mass, BMI, body fat mass, body fat percentage, body lean mass, and bone mineral content) between the placebo and synbiotic groups at the end of the clinical trial (3-month intervention, 20 human subjects participating in weight loss intervention based on a low-carbohydrate, high-protein, reduced energy diet). Synbiotic supplementation increased the abundance of gut bacteria associated with positive health effects, especially Bifidobacterium and Lactobacillus, and it also appeared to increase the gut microbiota richness. A decreasing trend in the gut microbiota diversity in the placebo and synbiotic groups was observed at the end of trial, which may imply the effect of the high-protein low-carbohydrate diet used in the weight loss program. Regression analysis performed to correlate abundance of species following supplementation with body composition parameters and biomarkers of obesity found an association between a decrease over time in blood glucose and an increase in Lactobacillus abundance, particularly in the synbiotic group. However, the decrease over time in body mass, BMI, waist circumstance, and body fat mass was associated with a decrease in Bifidobacterium abundance. The results obtained support the conclusion that synbiotic supplement used in this clinical trial modulates human gut microbiota by increasing abundance of potentially beneficial microbial species.

show abstract

“…Although the molecular pathways linking gut microbiota to the brain regulation of energy balance are not yet fully understood, modulation of gut microbiota composition by supplementing beneficial to health bacteria appears as an appealing new strategy for obesity prevention and treatment. Indeed, traditional probiotic bacteria belonging to the genera of Lactobacillus, Bifidobacterium, and Enterococcus, alone or in various combinations, have been tested in humans, resulting typically in minor health-positive effects, without significant changes in food intake and body weight [6][7][8][9]. Nevertheless, existence of the functional link between gut microbiota and host regulation of appetite and energy metabolism indicates that some gut commensal bacteria can be potentially identified and developed as new-generation anti-obesity probiotics based on the understanding of their mechanisms of action [10].We have recently demonstrated that a Hafnia alvei (H. alvei) HA4597™ strain of commensal bacteria of the Hafniaceae family (formerly Enterobacteriaceae) belonging to the order of Enterobacteriales displays anti-obesity properties in two animal models of obesity, standard-diet-fed leptin-deficient ob/ob and high-fat-diet (HFD)-fed wild-type (WT) mice [11].…”

mentioning

confidence: 99%

Hafnia alvei HA4597 Strain Reduces Food Intake and Body Weight Gain and Improves Body Composition, Glucose, and Lipid Metabolism in a Mouse Model of Hyperphagic Obesity

et al. 2019

View full text Add to dashboard Cite

Use of new generation probiotics may become an integral part of the prevention and treatment strategies of obesity. The aim of the present study was to test the efficacy of a potential probiotic strain of lactic bacteria Hafnia alvei (H. alvei) HA4597™, in a mouse model of obesity characterized by both hyperphagia and diet-induced adiposity. For this purpose, 10-week-old high-fat-diet (HFD)-fed hyperphagic ob/ob male mice received a daily treatment with 1.4 × 1010 CFU of H. alvei for 38 days. Effects of H. alvei were compared to those of a lipase inhibitor orlistat (80 mg/kg daily) and a vehicle (NaCl 0.9%) in HFD-fed ob/ob mice. A control untreated group of ob/ob mice received the standard diet throughout the experiment. The vehicle-treated HFD group displayed increased food intake, worsening of adiposity, and glycemia. Treatment with H. alvei was accompanied by decreased body weight and fat-mass gain along with reduced food intake to the level of the standard-diet-fed mice. At the end of the experiment, the group treated with H. alvei showed a decrease of glycemia, plasma total cholesterol, and alanine aminotransferase. The orlistat-treated mice showed a lower rate of body weight gain but were hyperphagic and hyperglycemic. These results demonstrate the beneficial anti-obesity and metabolic effects of H. alvei HA4597™ in mice with obesity resulting from hyperphagia and diet-induced adiposity.

show abstract

Effects of oral supplementation with probiotics or synbiotics in overweight and obese adults: a systematic review and meta-analyses of randomized trials

Cited by 62 publications

References 52 publications

A randomised controlled study shows supplementation of overweight and obese adults with lactobacilli and bifidobacteria reduces bodyweight and improves well-being

A randomised controlled study shows supplementation of overweight and obese adults with lactobacilli and bifidobacteria reduces bodyweight and improves well-being

Effects of Synbiotic Supplement on Human Gut Microbiota, Body Composition and Weight Loss in Obesity

Hafnia alvei HA4597 Strain Reduces Food Intake and Body Weight Gain and Improves Body Composition, Glucose, and Lipid Metabolism in a Mouse Model of Hyperphagic Obesity

Contact Info

Product

Resources

About